Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults.

Publication date: Nov 26, 2023

T cell immunity is key for the control of viral infections including SARS-CoV-2, in particular with regard to immune memory and protection against arising genetic variants. We recently evaluated a peptide-based SARS-CoV-2 T cell activator termed CoVac-1 in a first-in-human trial in healthy adults. Here, we report on long-term safety and efficacy data of CoVac-1 until month 12. CoVac-1 is well tolerated without long-term immune-related side effects and induces long-lasting anti-viral T cell responses in 100% of study participants, with potent expandability of CD4 and CD8 T cells targeting multiple different CoVac-1 T cell epitopes. T cell responses were associated with stronger injection site reaction. Beyond induction of T cell immunity, 89% of subjects developed CoVac-1-specific IgG antibodies which associated with the intensity of the T cell response, indicating that CoVac-1-specific CD4 T cells support the induction of B cell responses. Vaccination with approved COVID-19 vaccines boosted CoVac-1-specific T cell responses. Overall, a low SARS-CoV-2 infection rate (8. 3%) was observed. Together, a single application of CoVac-1 elicits long-lived and broad SARS-CoV-2-specific T cell immunity, which further supports the current evaluation of our T cell activator in patients with congenital or acquired B cell defects.

Concepts Keywords
Covid B cell deficiency
Genetic peptide
Month SARS-CoV-2
Vaccines T cell immunity
T cells


Type Source Name
disease MESH COVID-19
disease IDO cell
disease VO COVAC
disease MESH viral infections
disease VO report
disease MESH injection site reaction
disease VO vaccination
pathway REACTOME SARS-CoV-2 Infection
disease MESH defects
disease VO vaccine

Original Article

(Visited 1 times, 1 visits today)